CLINICAL TRIAL

whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy for Neoplasm Metastasis

1 Prior Treatment
Metastatic
Relapsed
Waitlist Available · 18+ · All Sexes · Vancouver, Canada

This study is evaluating whether a new radiotherapy technique called volumetric modulated arc therapy (VMAT) can be used to treat brain metastases.

See full description

About the trial for Neoplasm Metastasis

Eligible Conditions
Brain Neoplasms · Tumors Metastatic to Brain · Neoplasm Metastasis

Treatment Groups

This trial involves 2 different treatments. Whole Brain Radiotherapy (WBRT) And A Simultaneous Integrated Boost (SIB) Using Volumetric Modulated Arc Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
RADIATION
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Neoplasm Metastasis or one of the other 2 conditions listed above. There are 9 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
pathologically confirmed solid malignancy that was diagnosed within the past 5 years show original
We are available for your regular clinical and imaging follow up. show original
Age ≥ 18
1-10 brain metastases
No metastasis is larger than 3 cm in diameter. show original
KPS ≥ 70
The patient is stable neurologically, whether or not they are taking corticosteroids. show original
The individual has been successfully managing any extracranial health conditions and this is estimated to continue for a further six months. show original
The previous craniotomy allowed for better visualization of the lesion. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 1 year post-treatment
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year post-treatment
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 1 year post-treatment.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy will improve 1 primary outcome and 6 secondary outcomes in patients with Neoplasm Metastasis. Measurement will happen over the course of No time frame.

Median survival
NO TIME FRAME
NO TIME FRAME
Time to decline in cognition evaluated with the Mini-mental state examination
NO TIME FRAME
NO TIME FRAME
Time to decline in activities of daily living evaluated using the Modified Barthel index
NO TIME FRAME
NO TIME FRAME
3 month treatment response of metastases evaluated using contrast-enhanced MRI scan of brain
3 MONTHS POST TREATMENT
3 MONTHS POST TREATMENT
Both acute neurological toxicity (within 3 months of treatment) and late neurological toxicity (beyond 3 months of treatment
3 MONTHS AND BEYOND
3 MONTHS AND BEYOND
1-year local control of treated metastases evaluated with contrast-enhanced MRI scan of brain
1 YEAR POST-TREATMENT
1 YEAR POST-TREATMENT
See More

Who is running the study

Principal Investigator
A. N.
Alan Nichol, Radiation Oncologist
British Columbia Cancer Agency

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is neoplasm metastasis?

Metastasis may occur after curative resection of the primary tumor of the lung, colon or rectum, in the brain, and in lymph nodes. Metastasis can result in secondary cancer or seeding through the bloodstream and, in some cases, as neoplasm metastases after curative resection for the primary cancer. This is a rare form of cancer in the US, and the most frequent mode of cancer death is from a metastatic disease.

Anonymous Patient Answer

What are the signs of neoplasm metastasis?

This is the first study documenting the clinical manifestations of secondary lung tumors, especially in metastatic neoplasms. Recent findings  will be of help to the clinicians in dealing with patients at risk for primary  tumors and to optimize their management.

Anonymous Patient Answer

Can neoplasm metastasis be cured?

Because there is no cure of cancer metastasis, the focus should be on maintaining a long-term remission of cancer. A better understanding of the complex interplays involved in initiation and progression of metastatic neoplasm may yield a paradigm shift towards a better therapeutic approach for cancer metastasis.

Anonymous Patient Answer

What are common treatments for neoplasm metastasis?

There were no significant differences between men and women in the frequency of use of specific medications, but there was a significant difference in the frequency of use of chemotherapy.

Anonymous Patient Answer

How many people get neoplasm metastasis a year in the United States?

From 1990 to 1997 an average of 763 people per year were diagnosed with neoplasm metastasis in a SEER database of 20 million. Most neoplasm metastasis were primary lung and mammary tumor.

Anonymous Patient Answer

What causes neoplasm metastasis?

The cause of cancer metastasis is complex and is probably related to the development of specific tumour traits and to the particularity of the metastatic process in particular types of sarcoma.

Anonymous Patient Answer

Have there been any new discoveries for treating neoplasm metastasis?

In the future, new therapeutic interventions are needed; however, it was not possible to achieve a high level of remission in the present study. The most effective therapy with some degree of remission of neoplasm metastasis was used in patients with a high degree of metastasized disease that can cause high morbidity.

Anonymous Patient Answer

What is the latest research for neoplasm metastasis?

This summary is based on the following research articles:\n- "

"Rhinastutaceae\n\nRhinastutaceae is a family of fungi within the Trypetheliales order. The family has a widespread distribution, especially in temperate regions. Species in this family have small (about 2-3 mm) brownish fruit bodies that typically have clamp connections. Species in the family are often associated with woody conifers or hardwood trees. Known species in this family include "Rhinastorus uliginosus" (F.H. Møller) J.D. Rogers, and "Rhizophylla borinquena" (B.

Anonymous Patient Answer

What are the latest developments in whole brain radiotherapy (wbrt) and a simultaneous integrated boost (sib) using volumetric modulated arc therapy for therapeutic use?

SIB-WBRT demonstrates an increase in conformal arc dose, conformity, and conformal uniform dose in comparison with conventional WBRT. In a recent study, findings may help to improve the overall efficiency of radiation therapy and might result also in better tolerance of patients.

Anonymous Patient Answer

Does whole brain radiotherapy (wbrt) and a simultaneous integrated boost (sib) using volumetric modulated arc therapy improve quality of life for those with neoplasm metastasis?

WBRT and sib are both acceptable treatments for patients with neoplasm metastasis. Both methods appear to improve QOL over time. Further analysis is needed and these observations should be taken into account during treatment planning as baseline QOL scores and cognitive function are not well recorded.

Anonymous Patient Answer

Have there been other clinical trials involving whole brain radiotherapy (wbrt) and a simultaneous integrated boost (sib) using volumetric modulated arc therapy?

wbrt and sib are two effective modalities of treatment for metastatic [brain tumor](https://www.withpower.com/clinical-trials/brain-tumor)s. wbrt could be implemented in an effort to reduce toxicities of RT, especially for patients in the dose range of 25-54 Gy. sib could be a potential treatment option for patients who might undergo higher dose escalation, especially in order to achieve the maximum probability of tumor control.

Anonymous Patient Answer

How does whole brain radiotherapy (wbrt) and a simultaneous integrated boost (sib) using volumetric modulated arc therapy work?

This was a pilot study in an attempt to determine toxicity, control, response, and survival rates associated with wbrt and sib for glioblastoma multiforme patients. A prospective phase III trial will need to be established to confirm the results from this pilot study.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Neoplasm Metastasis by sharing your contact details with the study coordinator.